probenecid has been researched along with Stevens-Johnson Syndrome in 3 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Stevens-Johnson Syndrome: Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Studies found a strong association between allopurinol-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and the HLA-B*58:01 allele." | 7.88 | Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. ( Chaiyakunapruk, N; Chong, HY; Lim, YH; Mohamed, Z; Prawjaeng, J; Tassaneeyakul, W, 2018) |
| "Studies found a strong association between allopurinol-induced Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and the HLA-B*58:01 allele." | 3.88 | Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population. ( Chaiyakunapruk, N; Chong, HY; Lim, YH; Mohamed, Z; Prawjaeng, J; Tassaneeyakul, W, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chong, HY | 1 |
| Lim, YH | 1 |
| Prawjaeng, J | 1 |
| Tassaneeyakul, W | 1 |
| Mohamed, Z | 1 |
| Chaiyakunapruk, N | 1 |
| Zürcher, K | 1 |
| Krebs, A | 1 |
| Ström, J | 1 |
3 other studies available for probenecid and Stevens-Johnson Syndrome
| Article | Year |
|---|---|
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
Topics: Alleles; Allopurinol; Cost-Benefit Analysis; Female; Genetic Testing; Genotype; Heterozygote; HLA-B | 2018 |
[Cutaneous side effects of systemic drugs with special reference to recently introduced medicaments. I].
Topics: Allopurinol; Analgesics; Chlorothiazide; Colchicine; Drug Eruptions; Humans; Lichen Planus; Photosen | 1970 |
Ocular symptoms in febrile mucocutaneous reactions (ectodermosis erosiva pluriorificialis, Stevens-Johnson's syndrome, mucocutaneous-ocular syndrome etc.).
Topics: Cortisone; Eye Manifestations; Humans; Penicillins; Probenecid; Stevens-Johnson Syndrome | 1966 |